Investors & Media

Ionis presents positive results from Phase 3 NEURO-TTRansform study at International Symposium on Amyloidosis

Ionis and AstraZeneca’s eplontersen demonstrated a statistically significant and clinically meaningful change from baseline for co-primary and secondary endpoints at 35 weeks compared to the external placebo group Eplontersen achieved an 81.2% reduction in the co-primary endpoint of serum

Read more
You are now leaving https://www.ionispharma.com to visit